Categories: HealthcareNews

Genpact and STADA Renew Multi-Year Partnership to Enhance Finance Operations

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Leveraging Genpact’s data, technology and AI expertise to future-proof STADA’s finance organization and drive competitive advantages

NEW YORK, Sept. 12, 2024 /PRNewswire/ — Genpact (NYSE: G), a global professional services and solutions firm delivering outcomes that shape the future, and STADA (SAZ.DE), a leading manufacturer of consumer healthcare, generic and specialty pharma medicines, today announced the renewal of a multi-year partnership. The new chapter of innovation is aimed at further derisking, scaling, and simplifying STADA’s finance operations to drive competitive advantages.

“Genpact has enabled us to handle end-to-end tasks efficiently and cost-effectively,” – Boris Döbler, Group CFO, STADA.

“This renewal exemplifies our leadership in finance and accounting services,” said Sanjiv Tandon, Global Business Unit Leader, Life Sciences and Healthcare, Genpact. “By combining this expertise with our digital leadership and industry knowledge, we will enhance STADA’s decision-making with actionable finance data, automate key F&A processes, and support regulatory compliance – ultimately enabling the company to continuously scale and excel in its industry.”

Since 2019, Genpact’s partnership with STADA has centered on leveraging automation and process-harmonization to enhance critical operations. Implementing technologies such as Genpact’s Cora APFlow has improved the accuracy of critical processes such as accounts payable and receivable, streamlined data transparency, and empowered STADA’s teams to focus on strategic initiatives that drive business outcomes.

“STADA’s rapid growth and complex operations require a scalable and efficient platform. Our partnership with Genpact has enabled us to create automated processes that handle end-to-end tasks like procure-to-pay and order-to-cash efficiently and cost-effectively,” said Boris Döbler, Group Chief Financial Officer, STADA. “This allows our internal teams to focus on high-value activities. By leveraging data, analytics, and process automation, we’re not only reducing costs but also improving accuracy, quality, and customer satisfaction.”

Genpact has been instrumental in optimizing STADA’s finance and procurement processes, from supplier invoicing to financial reporting, leveraging advanced technology and deep finance and accounting expertise. Based on this strong foundation, the companies also are partnering to implement and leverage tools and technologies like S4HANA and generative AI.

For more information on Genpact’s capabilities and services for the life sciences and healthcare industries, visit here.

About Genpact
Genpact (NYSE: G) is a global professional services and solutions firm delivering outcomes that shape the future. Our 125,000+ people across 30+ countries are driven by our innate curiosity, entrepreneurial agility, and desire to create lasting value for clients. Powered by our purpose – the relentless pursuit of a world that works better for people – we serve and transform leading enterprises, including the Fortune Global 500, with our deep business and industry knowledge, digital operations services, and expertise in data, technology, and AI. 

Get to know us at genpact.com and on LinkedInXYouTube, and Facebook

MEDIA CONTACT:

Sue Martenson
Genpact Media Relations 
+1 978-905-9582
susan.martenson@genpact.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/genpact-and-stada-renew-multi-year-partnership-to-enhance-finance-operations-302245419.html

SOURCE Genpact Ltd.

Staff

Recent Posts

MedsEngine Achieves SOC 2 Type II Certification: Reinforcing Our Commitment to Data Security

DAYTON, Ohio--(BUSINESS WIRE)--MedsEngine, a provider of chronic disease management software, is proud to announce that…

2 hours ago

cbdMD, Inc. Announces Automatic Conversion Date of Series A Preferred Stock and One for Eight Reverse Split of its Common Stock Immediately Following the Automatic Conversion

Charlotte, North Carolina--(Newsfile Corp. - April 21, 2025) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…

11 hours ago

Onsite Mammography Provides Notice of Data Incident

BOSTON, April 21, 2025 /PRNewswire/ -- Onsite Mammography ("Onsite") announces a data incident that impacted…

14 hours ago

Lumenis Unveils Enhanced SPLENDOR X™ Laser Hair Removal Solution with New Clinical Data at the Annual American Society for Laser Medicine and Surgery (ASLMS) Conference

New data demonstrates effectiveness of SPLENDOR X™'s dual-wavelength simultaneous laser emission technology for improved hair…

14 hours ago

Havas Health Network and Republica Havas Health Unveil Report on Inequities in HCP Training and Practices

"The Hidden Divide" Exposes Gaps in Healthcare Provider Education and Care Delivery MIAMI, April 21,…

20 hours ago

K-679: A Novel Antibody Drug-loaded Unimicelle Conjugate with Ultra-High Drug Loading Capacity Demonstrates Superior Efficacy in EGFR-Expressing Solid Tumors

NAGOYA, Japan, April 21, 2025 /PRNewswire/ -- Kowa Company, Ltd. (Headquarters: Nagoya, Aichi Prefecture, Japan), today announced…

20 hours ago